Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model

Elizabeth R. Vogel, Logan J. Manlove, Ine Kuipers, Michael A. Thompson, Yun Hua Fang, Michelle R. Freeman, Rodney Jr. Britt, Arij Faksh, Binxia Yang, Y.s. Prakash, Christina M Pabelick

Research output: Contribution to journalArticle

Abstract

Reactive airway diseases are significant sources of pulmonary morbidity in neonatal and pediatric patients. Supplemental oxygen exposure in premature infants contributes to airway diseases such as asthma and promotes development of airway remodeling, characterized by increased airway smooth muscle (ASM) mass and extracellular matrix (ECM) deposition. Decreased plasma membrane caveolin-1 (CAV1) expression has been implicated in airway disease and may contribute to airway remodeling and hyperreactivity. Here, we investigated the impact of clinically relevant moderate hyperoxia (50% O2) on airway remodeling and caveolar protein expression in a neonatal mouse model. Within 12 h of birth, litters of B6129SF2J mice were randomized to room air (RA) or 50% hyperoxia exposure for 7 days with or without caveolin-1 scaffolding domain peptide (CSD; caveolin-1 mimic; 10 µl, 0.25 mM daily via intraperitoneal injection) followed by 14 days of recovery in normoxia. Moderate hyperoxia significantly increased airway reactivity and decreased pulmonary compliance at 3 wk. Histologic assessment demonstrated airway wall thickening and increased ASM mass following hyperoxia. RNA from isolated ASM demonstrated significant decreases in CAV1 and cavin-1 in hyperoxia-exposed animals while cavin-3 was increased. Supplementation with intraperitoneal CSD mitigated both the physiologic and histologic changes observed with hyperoxia. Overall, these data show that moderate hyperoxia is detrimental to developing airway and may predispose to airway reactivity and remodeling. Loss of CAV1 is one mechanism through which hyperoxia produces these deleterious effects. Supplementation of CAV1 using CSD or similar analogs may represent a new therapeutic avenue for blunting hyperoxia-induced pulmonary damage in neonates.

Original languageEnglish (US)
Pages (from-to)L99-L108
JournalAmerican journal of physiology. Lung cellular and molecular physiology
Volume317
Issue number1
DOIs
StatePublished - Jul 1 2019

Fingerprint

Airway Remodeling
Hyperoxia
Caveolin 1
Smooth Muscle
Lung Compliance
caveolin-1 (82-101)
Lung
Intraperitoneal Injections
Premature Infants
Extracellular Matrix
Asthma
Air
Cell Membrane
Parturition
RNA
Pediatrics
Oxygen
Morbidity

Keywords

  • airway smooth muscle
  • asthma
  • caveolin-1
  • extracellular matrix
  • hyperoxia
  • neonatal

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model. / Vogel, Elizabeth R.; Manlove, Logan J.; Kuipers, Ine; Thompson, Michael A.; Fang, Yun Hua; Freeman, Michelle R.; Britt, Rodney Jr.; Faksh, Arij; Yang, Binxia; Prakash, Y.s.; Pabelick, Christina M.

In: American journal of physiology. Lung cellular and molecular physiology, Vol. 317, No. 1, 01.07.2019, p. L99-L108.

Research output: Contribution to journalArticle

Vogel, Elizabeth R. ; Manlove, Logan J. ; Kuipers, Ine ; Thompson, Michael A. ; Fang, Yun Hua ; Freeman, Michelle R. ; Britt, Rodney Jr. ; Faksh, Arij ; Yang, Binxia ; Prakash, Y.s. ; Pabelick, Christina M. / Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model. In: American journal of physiology. Lung cellular and molecular physiology. 2019 ; Vol. 317, No. 1. pp. L99-L108.
@article{9915eabfa92b40b6834193ad94ce5a11,
title = "Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model",
abstract = "Reactive airway diseases are significant sources of pulmonary morbidity in neonatal and pediatric patients. Supplemental oxygen exposure in premature infants contributes to airway diseases such as asthma and promotes development of airway remodeling, characterized by increased airway smooth muscle (ASM) mass and extracellular matrix (ECM) deposition. Decreased plasma membrane caveolin-1 (CAV1) expression has been implicated in airway disease and may contribute to airway remodeling and hyperreactivity. Here, we investigated the impact of clinically relevant moderate hyperoxia (50{\%} O2) on airway remodeling and caveolar protein expression in a neonatal mouse model. Within 12 h of birth, litters of B6129SF2J mice were randomized to room air (RA) or 50{\%} hyperoxia exposure for 7 days with or without caveolin-1 scaffolding domain peptide (CSD; caveolin-1 mimic; 10 µl, 0.25 mM daily via intraperitoneal injection) followed by 14 days of recovery in normoxia. Moderate hyperoxia significantly increased airway reactivity and decreased pulmonary compliance at 3 wk. Histologic assessment demonstrated airway wall thickening and increased ASM mass following hyperoxia. RNA from isolated ASM demonstrated significant decreases in CAV1 and cavin-1 in hyperoxia-exposed animals while cavin-3 was increased. Supplementation with intraperitoneal CSD mitigated both the physiologic and histologic changes observed with hyperoxia. Overall, these data show that moderate hyperoxia is detrimental to developing airway and may predispose to airway reactivity and remodeling. Loss of CAV1 is one mechanism through which hyperoxia produces these deleterious effects. Supplementation of CAV1 using CSD or similar analogs may represent a new therapeutic avenue for blunting hyperoxia-induced pulmonary damage in neonates.",
keywords = "airway smooth muscle, asthma, caveolin-1, extracellular matrix, hyperoxia, neonatal",
author = "Vogel, {Elizabeth R.} and Manlove, {Logan J.} and Ine Kuipers and Thompson, {Michael A.} and Fang, {Yun Hua} and Freeman, {Michelle R.} and Britt, {Rodney Jr.} and Arij Faksh and Binxia Yang and Y.s. Prakash and Pabelick, {Christina M}",
year = "2019",
month = "7",
day = "1",
doi = "10.1152/ajplung.00111.2018",
language = "English (US)",
volume = "317",
pages = "L99--L108",
journal = "American Journal of Physiology",
issn = "1040-0605",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Caveolin-1 scaffolding domain peptide prevents hyperoxia-induced airway remodeling in a neonatal mouse model

AU - Vogel, Elizabeth R.

AU - Manlove, Logan J.

AU - Kuipers, Ine

AU - Thompson, Michael A.

AU - Fang, Yun Hua

AU - Freeman, Michelle R.

AU - Britt, Rodney Jr.

AU - Faksh, Arij

AU - Yang, Binxia

AU - Prakash, Y.s.

AU - Pabelick, Christina M

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Reactive airway diseases are significant sources of pulmonary morbidity in neonatal and pediatric patients. Supplemental oxygen exposure in premature infants contributes to airway diseases such as asthma and promotes development of airway remodeling, characterized by increased airway smooth muscle (ASM) mass and extracellular matrix (ECM) deposition. Decreased plasma membrane caveolin-1 (CAV1) expression has been implicated in airway disease and may contribute to airway remodeling and hyperreactivity. Here, we investigated the impact of clinically relevant moderate hyperoxia (50% O2) on airway remodeling and caveolar protein expression in a neonatal mouse model. Within 12 h of birth, litters of B6129SF2J mice were randomized to room air (RA) or 50% hyperoxia exposure for 7 days with or without caveolin-1 scaffolding domain peptide (CSD; caveolin-1 mimic; 10 µl, 0.25 mM daily via intraperitoneal injection) followed by 14 days of recovery in normoxia. Moderate hyperoxia significantly increased airway reactivity and decreased pulmonary compliance at 3 wk. Histologic assessment demonstrated airway wall thickening and increased ASM mass following hyperoxia. RNA from isolated ASM demonstrated significant decreases in CAV1 and cavin-1 in hyperoxia-exposed animals while cavin-3 was increased. Supplementation with intraperitoneal CSD mitigated both the physiologic and histologic changes observed with hyperoxia. Overall, these data show that moderate hyperoxia is detrimental to developing airway and may predispose to airway reactivity and remodeling. Loss of CAV1 is one mechanism through which hyperoxia produces these deleterious effects. Supplementation of CAV1 using CSD or similar analogs may represent a new therapeutic avenue for blunting hyperoxia-induced pulmonary damage in neonates.

AB - Reactive airway diseases are significant sources of pulmonary morbidity in neonatal and pediatric patients. Supplemental oxygen exposure in premature infants contributes to airway diseases such as asthma and promotes development of airway remodeling, characterized by increased airway smooth muscle (ASM) mass and extracellular matrix (ECM) deposition. Decreased plasma membrane caveolin-1 (CAV1) expression has been implicated in airway disease and may contribute to airway remodeling and hyperreactivity. Here, we investigated the impact of clinically relevant moderate hyperoxia (50% O2) on airway remodeling and caveolar protein expression in a neonatal mouse model. Within 12 h of birth, litters of B6129SF2J mice were randomized to room air (RA) or 50% hyperoxia exposure for 7 days with or without caveolin-1 scaffolding domain peptide (CSD; caveolin-1 mimic; 10 µl, 0.25 mM daily via intraperitoneal injection) followed by 14 days of recovery in normoxia. Moderate hyperoxia significantly increased airway reactivity and decreased pulmonary compliance at 3 wk. Histologic assessment demonstrated airway wall thickening and increased ASM mass following hyperoxia. RNA from isolated ASM demonstrated significant decreases in CAV1 and cavin-1 in hyperoxia-exposed animals while cavin-3 was increased. Supplementation with intraperitoneal CSD mitigated both the physiologic and histologic changes observed with hyperoxia. Overall, these data show that moderate hyperoxia is detrimental to developing airway and may predispose to airway reactivity and remodeling. Loss of CAV1 is one mechanism through which hyperoxia produces these deleterious effects. Supplementation of CAV1 using CSD or similar analogs may represent a new therapeutic avenue for blunting hyperoxia-induced pulmonary damage in neonates.

KW - airway smooth muscle

KW - asthma

KW - caveolin-1

KW - extracellular matrix

KW - hyperoxia

KW - neonatal

UR - http://www.scopus.com/inward/record.url?scp=85068810669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068810669&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00111.2018

DO - 10.1152/ajplung.00111.2018

M3 - Article

VL - 317

SP - L99-L108

JO - American Journal of Physiology

JF - American Journal of Physiology

SN - 1040-0605

IS - 1

ER -